


PHARMACEUTICAL 2017

SCICLONE PHARMACEUTICALS INC Rank 8 of 313





PHARMACEUTICAL 2017



SCICLONE PHARMACEUTICALS INC Rank 8 of 313

The relative strengths and weaknesses of SCICLONE PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCICLONE PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 551% points. The greatest weakness of SCICLONE PHARMACEUTICALS INC is the variable Other Expenses, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 681% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	195,733
Cost of Goods Sold	0
Intangible Assets	30,838
Liabilities, Current	26,441
Liabilities, Non-Current	0
Other Assets	13,325
Other Compr. Net Income	-3,590
Other Expenses	96,084
Other Liabilities	0
Other Net Income	898
Property and Equipment	2,002
Research and Development	0
Revenues	160,096
Selling, General and Administrative Expense	34,181

Output Variable	Value in 1000 USD
Assets	241,898
Liabilities	26,441
Expenses	130,265
Stockholders Equity	215,457
Net Income	30,729
Comprehensive Net Income	28,934
Economic Capital Ratio	264%